Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4
S. A. Camolotto, V. Belova, L. Torre-Healy, J. Vahrenkamp, K. Berrett, H. Conway, C. Stubben, R. Moffitt, J. Gertz, E. Snyder
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a five-year survival of less than 5%. Transcriptomic analysis has identified two clinically relevant molecular subtypes of PDAC: Classical and Basal-like. The Classical subtype is characterized by a more favorable prognosis and better response to chemotherapy than the Basal-like subtype. The Classical subtype also expresses higher levels of lineage specifiers that regulate endodermal differentiation, including the nuclear receptor HNF4. Using in vitro and in vivo PDAC models, we show that HNF4 restrains tumor growth and drives tumor cells toward an epithelial identity. Gene expression analysis from murine models and human tumors shows that HNF4 activates expression of genes associated with the Classical subtype. Although HNF4 loss is not sufficient for complete conversion to the Basal-like subtype gene expression profile, HNF4 directly represses SIX4 and SIX1, mesodermal lineage specifiers expressed in the Basal-like subtype. Finally, HNF4-negative PDAC cells rely on expression of SIX4 and SIX1 for proliferation in vitro and in vivo. Overall, our data show that HNF4 regulates the growth and molecular subtype of PDAC by multiple mechanisms, including activation of the Classical gene expression program and repression of SIX4 and SIX1, which may represent novel dependencies of the Basal-like subtype.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Differential control of growth and identity by HNF4α isoforms in pancreatic ductal adenocarcinoma
Pengshu Fang, Emily R. Wilson, … Eric L. Snyder·Molecular Cancer ResearchPeer-reviewed·Jul 16, 2025
- HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma
Kennedy S. Humphrey, Katherine J. Crawford, … Ethan V. Abel·Communications BiologyPeer-reviewed·Jul 30, 2026
- Basal-to-classical phenotypic switch of pancreatic cancer cells upon integration into the duodenal epithelium
B. Bozoky, C. Fernandez Moro, … B. Bozoky·bioRxiv·Feb 1, 2021
- A GATA6-centered gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer
P. Martinelli, B. Kloesch, … F. X. Real·GutPeer-reviewed·Apr 12, 2021
- HNF1A is a Novel Oncogene and Central Regulator of Pancreatic Cancer Stem Cells
E. Abel, M. Goto, … D. M. Simeone·bioRxiv·Dec 22, 2017
- ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer
Paloma Moreno, Yuuki Ohara, … S. Perwez Hussain·CarcinogenesisPeer-reviewed·Aug 12, 2024